Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 139

Showing 1-25 of 139 citing articles:

Changing epidemiology, global trends and implications for outcomes of NAFLD
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 842-852
Open Access | Times Cited: 264
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, et al.
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 5, pp. 575-594
Open Access | Times Cited: 70
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
Zobair M. Younossi, Pegah Golabi, Jillian Kallman Price, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 10, pp. 1999-2010.e8
Closed Access | Times Cited: 48
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
Juan Patricio Nogueira, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 20-28
Open Access | Times Cited: 39
Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment
R. I. G. Holt, Clive S. Cockram, Ronald C.W., et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1168-1180
Open Access | Times Cited: 29
Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH
Kenneth Cusi
New England Journal of Medicine (2024) Vol. 390, Iss. 6, pp. 559-561
Closed Access | Times Cited: 27
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Idoia Genua, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 48-58
Open Access | Times Cited: 27
Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study
Quentin M. Anstee, Tina Landsvig Berentzen, Louise Maymann Nitze, et al.
The Lancet Regional Health - Europe (2023) Vol. 36, pp. 100780-100780
Open Access | Times Cited: 37
Diabetes and cirrhosis: Current concepts on diagnosis and management
Laurent Castéra, Kenneth Cusi
Hepatology (2023) Vol. 77, Iss. 6, pp. 2128-2146
Closed Access | Times Cited: 36
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment
Stefano Ciardullo, Michela Vergani, Gianluca Perseghin
Journal of Clinical Medicine (2023) Vol. 12, Iss. 17, pp. 5597-5597
Open Access | Times Cited: 31
Implementation of a liver health check in people with type 2 diabetes
Kushala Abeysekera, Luca Valenti, Zobair M. Younossi, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 9, Iss. 1, pp. 83-91
Open Access | Times Cited: 29
Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study
Raffaele Napoli, Cesare Berra, Andrei‐Mircea Catarig, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1658-1667
Open Access | Times Cited: 22
Advances in the management of type 2 diabetes in adults
Rodolfo J. Galindo, Jennifer M. Trujillo, Cecilia C. Low Wang, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000372-e000372
Open Access | Times Cited: 21
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
Xiaolong Qi, Jie Li, Cyrielle Caussy, et al.
Hepatology (2024)
Open Access | Times Cited: 12
New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment
Dania Haddad, Vanessa Sybil Dsouza, Fahd Al‐Mulla, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 1, pp. 571-571
Open Access | Times Cited: 10
Diabetes as a risk factor for MASH progression
Sofiya Gancheva, Michael Roden, Laurent Castéra
Diabetes Research and Clinical Practice (2024) Vol. 217, pp. 111846-111846
Open Access | Times Cited: 8
Prevalence and co-prevalence of comorbidities among Chinese adult patients with type 2 diabetes mellitus: a cross-sectional, multicenter, retrospective, observational study based on 3B study database
Qiuhe Ji, Shangyu Chai, Ruya Zhang, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 7
Effects of Hypoglycemia on Cardiovascular Function in Patients with Diabetes
María Christou, Panagiota A. Christou, Christos Kyriakopoulos, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9357-9357
Open Access | Times Cited: 17
Current scientific evidence for why periodontitis should be included in diabetes management
Wenche S. Borgnakke
Frontiers in Clinical Diabetes and Healthcare (2024) Vol. 4
Open Access | Times Cited: 6
Nonalcoholic Fatty Liver Disease in Diabetes: A Call to Action
Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 5-7
Open Access | Times Cited: 6
The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
Francisco Barrera, Javier Uribe, Nixa Olvares, et al.
Annals of Hepatology (2024) Vol. 29, Iss. 4, pp. 101501-101501
Open Access | Times Cited: 6
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease
Xianhua Mao, Xinrong Zhang, Leslie Y. Kam, et al.
Gut (2024) Vol. 73, Iss. 12, pp. 2054-2061
Closed Access | Times Cited: 5
Factors determining first influenza vaccination among individuals with type 2 diabetes in the CONSTANCES cohort by age group (younger than 65 years or 65 and older)
Sylvain Paquet, Virginie Ringa, Henri Panjo, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus
Mengmeng Hu, Jingyu Yang, Beibei Gao, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Comparison of Referral Rates and Costs Using Fibrosis-4 and Enhanced Liver Fibrosis (ELF) Testing Strategies for Initial Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Veteran Population
Samrat Yeramaneni, Stephanie T. Chang, Ramsey Cheung, et al.
The Journal of Applied Laboratory Medicine (2025)
Closed Access
Page 1 - Next Page

Scroll to top